Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I

NCT02702115 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class

Stopped All three subjects dosed in the study have rolled over to the Long-Term Follow-up Study IVPRP-LT01 (NCT04628871)

Conditions

Interventions

Sponsor

Sangamo Therapeutics